Protagenic Therapeutics, Inc.

Equities

PTIX

US74365N2027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.44 ^USD	-4.01%		+7.05%	+45.45%

May. 01	Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	CI
Apr. 01	Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Protagenic Therapeutics, Inc. has completed an IPO in the amount of $13.197 million.

April 26, 2021 at 12:00 am EDT

Protagenic Therapeutics, Inc. has completed an IPO in the amount of $13.197 million.

Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 3,180,000
PriceRange: $4.15
Discount Per Security: $0.332

Latest news about Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	May. 01	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders	Mar. 27	CI
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	Feb. 13	CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	Dec. 12	MT
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	Dec. 12	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director	22-11-29	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-07	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Maxim Group Starts Protagenic Therapeutics at Buy with $4 Price Target	21-10-29	MT
Certain Warrant of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	21-10-23	CI
Certain Common Stock of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	21-10-23	CI
Certain Stock Options of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	21-10-23	CI
Protagenic Therapeutics, Inc. Announces Audit Committee Changes	21-10-05	CI
Transcript : Protagenic Therapeutics, Inc. - Special Call	21-09-08
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Protagenic Therapeutics : Expects to Refile New Drug Application in Q4 After Implementing Change Requested by FDA	21-07-23	MT
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial	21-07-23	CI

Chart Protagenic Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTAGENIC THERAPEUTICS, INC.	+45.45%	6.65M
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research